17.75
price down icon1.93%   -0.35
after-market After Hours: 16.87 -0.88 -4.96%
loading
Travere Therapeutics Inc stock is traded at $17.75, with a volume of 863.48K. It is down -1.93% in the last 24 hours and up +16.55% over the past month. Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN) - rare kidney disorders that often cause end-stage kidney disease.
See More
Previous Close:
$18.10
Open:
$18.05
24h Volume:
863.48K
Relative Volume:
0.50
Market Cap:
$1.39B
Revenue:
$198.84M
Net Income/Loss:
$-111.40M
P/E Ratio:
-3.927
EPS:
-4.52
Net Cash Flow:
$-322.28M
1W Performance:
-3.38%
1M Performance:
+16.55%
6M Performance:
+183.55%
1Y Performance:
+154.66%
1-Day Range:
Value
$17.32
$18.10
1-Week Range:
Value
$16.77
$18.90
52-Week Range:
Value
$5.12
$19.25

Travere Therapeutics Inc Stock (TVTX) Company Profile

Name
Name
Travere Therapeutics Inc
Name
Phone
888-969-7879
Name
Address
3611 VALLEY CENTRE DR, SAN DIEGO
Name
Employee
380
Name
Twitter
Name
Next Earnings Date
2024-10-31
Name
Latest SEC Filings
Name
TVTX's Discussions on Twitter

Travere Therapeutics Inc Stock (TVTX) Upgrades & Downgrades

Date Action Analyst Rating Change
Mar-27-24 Downgrade Guggenheim Buy → Neutral
Dec-05-23 Upgrade Citigroup Neutral → Buy
Nov-20-23 Initiated Citigroup Neutral
Sep-22-23 Downgrade Wells Fargo Overweight → Equal Weight
Sep-21-23 Downgrade William Blair Outperform → Mkt Perform
Sep-06-23 Resumed Evercore ISI Outperform
Jul-21-23 Initiated JP Morgan Overweight
Jun-07-23 Resumed Piper Sandler Neutral
May-22-23 Initiated TD Cowen Outperform
May-05-23 Upgrade Bryan Garnier Sell → Neutral
Mar-01-23 Initiated Guggenheim Buy
Feb-21-23 Upgrade Wedbush Neutral → Outperform
Dec-14-22 Initiated Stifel Hold
Dec-05-22 Initiated Wells Fargo Overweight
Sep-21-22 Initiated Bryan Garnier Sell
Jul-14-22 Resumed Canaccord Genuity Buy
Mar-31-22 Initiated Piper Sandler Overweight
Feb-28-22 Initiated H.C. Wainwright Buy
May-26-21 Downgrade Wedbush Outperform → Neutral
View All

Travere Therapeutics Inc Stock (TVTX) Latest News

pulisher
04:19 AM

Vanguard Group Inc's Strategic Acquisition in Travere Therapeuti - GuruFocus.com

04:19 AM
pulisher
Nov 04, 2024

Travere Therapeutics (TVTX) Reports Q3 Loss, Tops Revenue Estimates - MSN

Nov 04, 2024
pulisher
Nov 04, 2024

Travere Therapeutics to Present at Upcoming Investor Conferences - The Manila Times

Nov 04, 2024
pulisher
Nov 03, 2024

Travere Therapeutics, Inc. (NASDAQ:TVTX) Holdings Raised by Emerald Mutual Fund Advisers Trust - MarketBeat

Nov 03, 2024
pulisher
Nov 03, 2024

Travere Therapeutics (NASDAQ:TVTX) Stock Price Expected to Rise, Scotiabank Analyst Says - Defense World

Nov 03, 2024
pulisher
Nov 01, 2024

Travere Therapeutics (NASDAQ:TVTX) Stock Price Expected to Rise, Barclays Analyst Says - MarketBeat

Nov 01, 2024
pulisher
Nov 01, 2024

Evercore ISI raises Travere Therapeutics target to $33 By Investing.com - Investing.com Australia

Nov 01, 2024
pulisher
Nov 01, 2024

Travere Therapeutics Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance

Nov 01, 2024
pulisher
Nov 01, 2024

Travere Therapeutics, Inc. (NASDAQ:TVTX) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 01, 2024
pulisher
Nov 01, 2024

Travere Therapeutics Inc (TVTX) Q3 2024 Earnings Call Highlights: Strong Sales Growth Amid Operational Challenges - GuruFocus.com

Nov 01, 2024
pulisher
Nov 01, 2024

Travere Therapeutics Boosts Sales with FILSPARI Approval - TipRanks

Nov 01, 2024
pulisher
Oct 31, 2024

Travere Therapeutics, Inc.'s (NASDAQ:TVTX) Shares Bounce 27% But Its Business Still Trails The Industry - Simply Wall St

Oct 31, 2024
pulisher
Oct 31, 2024

Travere: Q3 Earnings Snapshot - The Washington Post

Oct 31, 2024
pulisher
Oct 31, 2024

Travere Therapeutics earnings beat by $1.34, revenue topped estimates - Investing.com Australia

Oct 31, 2024
pulisher
Oct 31, 2024

Travere Therapeutics Inc Reports Q3 2024 Revenue of $62.9 Millio - GuruFocus.com

Oct 31, 2024
pulisher
Oct 31, 2024

Travere Therapeutics Reports Third Quarter 2024 Financial Results - The Manila Times

Oct 31, 2024
pulisher
Oct 30, 2024

Travere Therapeutics Inc (TVTX) Q3 2024 Earnings Report Preview: What to Expect - GuruFocus.com

Oct 30, 2024
pulisher
Oct 29, 2024

TD Cowen reiterates Buy on Travere shares after PARASOL findings By Investing.com - Investing.com Canada

Oct 29, 2024
pulisher
Oct 29, 2024

Semanteon Capital Management LP Purchases Shares of 36,699 Travere Therapeutics, Inc. (NASDAQ:TVTX) - MarketBeat

Oct 29, 2024
pulisher
Oct 28, 2024

Travere presents data reinforcing clinical benefit of FILSPARI in IgAN - Yahoo Finance

Oct 28, 2024
pulisher
Oct 27, 2024

Travere Therapeutics, Inc. (NASDAQ:TVTX) Shares Sold by Assenagon Asset Management S.A. - MarketBeat

Oct 27, 2024
pulisher
Oct 26, 2024

Travere Therapeutics Presents Data Reinforcing Clinical Benefit of FILSPARI® (Sparsentan) in IgAN and Late-Breaking Presentation in FSGS at ASN Kidney Week 2024 - The Manila Times

Oct 26, 2024
pulisher
Oct 25, 2024

TSX Income Trust Index (RTCM) QuotePress Release - The Globe and Mail

Oct 25, 2024
pulisher
Oct 25, 2024

(TVTX) Trading Report - Stock Traders Daily

Oct 25, 2024
pulisher
Oct 24, 2024

Jim Cramer Says 'Hold On' To Palantir, 'Let Them Walk It - EMEA Tribune, Breaking News, World News, Latest News, Top Headlines

Oct 24, 2024
pulisher
Oct 24, 2024

Travere Therapeutics (TVTX) to Release Quarterly Earnings on Thursday - MarketBeat

Oct 24, 2024
pulisher
Oct 24, 2024

Jim Cramer Says 'Hold On' To Palantir, 'Let Them Walk It Up'; Warns That Travere Therapeutics Is Losing A 'Ton Of Money' - Yahoo Finance

Oct 24, 2024
pulisher
Oct 23, 2024

Wall Street Analysts See a 26.27% Upside in Travere (TVTX): Can the Stock Really Move This High? - MSN

Oct 23, 2024
pulisher
Oct 21, 2024

Travere Therapeutics to Report Third Quarter 2024 Financial Results - The Manila Times

Oct 21, 2024
pulisher
Oct 21, 2024

Travere Therapeutics (NASDAQ:TVTX) Shares Gap UpTime to Buy? - MarketBeat

Oct 21, 2024
pulisher
Oct 21, 2024

Travere Therapeutics (NASDAQ:TVTX) Upgraded at Wells Fargo & Company - MarketBeat

Oct 21, 2024
pulisher
Oct 21, 2024

Travere Therapeutics Stock: A Deep Dive Into Analyst Perspectives (24 Ratings) - Benzinga

Oct 21, 2024
pulisher
Oct 21, 2024

Wells Fargo raises Travere Therapeutics stock to Overweight rating By Investing.com - Investing.com Canada

Oct 21, 2024
pulisher
Oct 18, 2024

State Street Corp's Strategic Reduction in Travere Therapeutics Holdings - GuruFocus.com

Oct 18, 2024
pulisher
Oct 18, 2024

TVTX stock soars to 52-week high, hits $18.63 amid robust gains - Investing.com Australia

Oct 18, 2024
pulisher
Oct 17, 2024

Travere Therapeutics (NASDAQ:TVTX) Hits New 1-Year HighHere's Why - MarketBeat

Oct 17, 2024
pulisher
Oct 17, 2024

TVTX stock soars to 52-week high, hits $18.63 amid robust gains By Investing.com - Investing.com South Africa

Oct 17, 2024
pulisher
Oct 17, 2024

Travere Therapeutics and CSL Vifor Announce Swissmedic Approval of FILSPARI® (sparsentan) for the Treatment of IgA Nephropathy - StockTitan

Oct 17, 2024
pulisher
Oct 17, 2024

CSL Vifor and Travere Therapeutics Announce Swissmedic approval of FILSPARI® (sparsentan) for the treatment of IgA Nephropathy - PR Newswire

Oct 17, 2024
pulisher
Oct 16, 2024

Breaking Down Travere Therapeutics: 23 Analysts Share Their Views - Benzinga

Oct 16, 2024
pulisher
Oct 16, 2024

Travere Therapeutics (NASDAQ:TVTX) Earns Sector Outperform Rating from Analysts at Scotiabank - MarketBeat

Oct 16, 2024
pulisher
Oct 16, 2024

Travere Therapeutics, Inc. (NASDAQ:TVTX) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat

Oct 16, 2024
pulisher
Oct 15, 2024

Investing in Travere Therapeutics Inc (TVTX) Is Getting More Attractive - Knox Daily

Oct 15, 2024
pulisher
Oct 15, 2024

Travere Therapeutics to Present Abstracts at American Society of Nephrology (ASN) Kidney Week 2024 - The Manila Times

Oct 15, 2024
pulisher
Oct 15, 2024

Travere Awaits FDA Ruling On Rare Kidney Disease Drug - RTTNews

Oct 15, 2024

Travere Therapeutics Inc Stock (TVTX) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Travere Therapeutics Inc Stock (TVTX) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
LYONS GARY A
Director
Oct 04 '24
Sale
14.73
40,000
589,101
51,000
$77.28
price up icon 2.02%
$20.39
price up icon 2.15%
$382.77
price up icon 1.58%
$53.29
price down icon 0.47%
$208.03
price up icon 0.38%
$110.97
price up icon 1.84%
Cap:     |  Volume (24h):